174 related articles for article (PubMed ID: 15779426)
1. [NAVIGATOR trial (nateglinide)].
Tsujii S
Nihon Rinsho; 2005 Feb; 63 Suppl 2():483-7. PubMed ID: 15779426
[No Abstract] [Full Text] [Related]
2. [Effects of nateglinide in impaired glucose tolerance subjects].
Hirose T
Nihon Rinsho; 2005 Feb; 63 Suppl 2():438-43. PubMed ID: 15779419
[No Abstract] [Full Text] [Related]
3. [Clinical trial of AY4166].
Kikuchi M
Nihon Rinsho; 1997 Nov; 55 Suppl():164-70. PubMed ID: 9434462
[No Abstract] [Full Text] [Related]
4. Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
Krum H; McMurray JJ; Horton E; Gerlock T; Holzhauer B; Zuurman L; Haffner SM; Bethel MA; Holman RR; Califf RM
Cardiovasc Ther; 2010 Apr; 28(2):124-32. PubMed ID: 20184589
[TBL] [Abstract][Full Text] [Related]
5. [The Study TO Prevent Non-Insulin Dependent Diabetes Mellitus trial (acarbose)].
Nishimura R
Nihon Rinsho; 2005 Feb; 63 Suppl 2():478-82. PubMed ID: 15779425
[No Abstract] [Full Text] [Related]
6. [Diabetes prevention program (metformin)].
Kusaka I; Nagasaka S
Nihon Rinsho; 2005 Feb; 63 Suppl 2():471-7. PubMed ID: 15779424
[No Abstract] [Full Text] [Related]
7. [Therapies for newly-onset diabetic patients].
Kawamori R
Nihon Rinsho; 2005 Feb; 63 Suppl 2():525-32. PubMed ID: 15779435
[No Abstract] [Full Text] [Related]
8. [Progress in therapy for diabetes mellitus--insulin-secretion inducing oral hypoglycemic agents].
Nagashima K; Inagaki N
Nihon Naika Gakkai Zasshi; 2009 Apr; 98(4):737-41. PubMed ID: 19472523
[No Abstract] [Full Text] [Related]
9. Effect of nateglinide on the incidence of diabetes and cardiovascular events.
; Holman RR; Haffner SM; McMurray JJ; Bethel MA; Holzhauer B; Hua TA; Belenkov Y; Boolell M; Buse JB; Buckley BM; Chacra AR; Chiang FT; Charbonnel B; Chow CC; Davies MJ; Deedwania P; Diem P; Einhorn D; Fonseca V; Fulcher GR; Gaciong Z; Gaztambide S; Giles T; Horton E; Ilkova H; Jenssen T; Kahn SE; Krum H; Laakso M; Leiter LA; Levitt NS; Mareev V; Martinez F; Masson C; Mazzone T; Meaney E; Nesto R; Pan C; Prager R; Raptis SA; Rutten GE; Sandstroem H; Schaper F; Scheen A; Schmitz O; Sinay I; Soska V; Stender S; Tamás G; Tognoni G; Tuomilehto J; Villamil AS; Vozár J; Califf RM
N Engl J Med; 2010 Apr; 362(16):1463-76. PubMed ID: 20228402
[TBL] [Abstract][Full Text] [Related]
10. Effects of nateglinide on the secretion of glycated insulin and glucose tolerance in type 2 diabetes.
Lindsay JR; McKillop AM; Mooney MH; O'Harte FP; Flatt PR; Bell PM
Diabetes Res Clin Pract; 2003 Sep; 61(3):167-73. PubMed ID: 12965106
[TBL] [Abstract][Full Text] [Related]
11. International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial.
Harumi Higuchi Dos Santos M; Sharma A; Sun JL; Pieper K; McMurray JJ; Holman RR; Lopes RD
J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28087508
[TBL] [Abstract][Full Text] [Related]
12. Venous thromboembolism and cardiovascular risk: results from the NAVIGATOR trial.
Katz M; Califf RM; Sun JL; McMurray JJ; Thomas L; Lopes RD
Am J Med; 2015 Mar; 128(3):297-302. PubMed ID: 25447626
[TBL] [Abstract][Full Text] [Related]
13. Effect of the administration of a single dose of nateglinide on insulin secretion at two different concentrations of glucose in healthy individuals.
González-Ortiz M; Hernández-Salazar E; Martínez-Abundis E
J Diabetes Complications; 2005; 19(6):356-60. PubMed ID: 16260353
[TBL] [Abstract][Full Text] [Related]
14. Weight loss-associated changes in acute effects of nateglinide on insulin secretion after glucose loading: results of glucose loading on 2 consecutive days.
Mori Y; Mamori S; Tajima N
Diabetes Obes Metab; 2005 Mar; 7(2):182-8. PubMed ID: 15715891
[TBL] [Abstract][Full Text] [Related]
15. [Glinide(s), sulfonylurea(s)].
Arakawa M; Hirose T
Nihon Rinsho; 2006 Nov; 64(11):2107-12. PubMed ID: 17087304
[TBL] [Abstract][Full Text] [Related]
16. Beta-cell function in mild type 2 diabetic patients: effects of 6-month glucose lowering with nateglinide.
Mari A; Gastaldelli A; Foley JE; Pratley RE; Ferrannini E
Diabetes Care; 2005 May; 28(5):1132-8. PubMed ID: 15855578
[TBL] [Abstract][Full Text] [Related]
17. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.
Califf RM; Boolell M; Haffner SM; Bethel M; McMurray J; Duggal A; Holman RR;
Am Heart J; 2008 Oct; 156(4):623-32. PubMed ID: 18946890
[TBL] [Abstract][Full Text] [Related]
18. [NAVIGATOR: A trial of prevention of cardiovascular complications and type 2 diabetes with valsartan and/or nateglinide].
Scheen AJ
Rev Med Liege; 2010 Apr; 65(4):217-23. PubMed ID: 20499825
[TBL] [Abstract][Full Text] [Related]
19. Nateglinide.
Dunn CJ; Faulds D
Drugs; 2000 Sep; 60(3):607-615; discussion 616-7. PubMed ID: 11030470
[TBL] [Abstract][Full Text] [Related]
20. [Nateglinide and mitiglinide].
Odawara M
Nihon Rinsho; 2003 Jul; 61(7):1230-7. PubMed ID: 12877090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]